What is claimed is:

1. A compound of formula (I):



(I)

and pharmaceutically acceptable salts, tautomers, stereoisomers, enantiomers, and isotopologues~~, and prodrugs~~ thereof,

wherein:

R^1 is substituted or unsubstituted C_{1-8} alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted non-aromatic heterocyclyl, substituted or unsubstituted alkylcycloalkyl, or substituted or unsubstituted alkylheterocyclyl, provided that R^1 is not 1-aminocyclohexyl;

R^2 is substituted or unsubstituted C_{1-8} alkyl, substituted or unsubstituted saturated cycloalkyl, or substituted or unsubstituted non-aromatic heterocyclyl;

provided the compound is not

2-(2-aminoethylamino)-4-(methylamino)pyrimidine-5-carboxamide,

2-(2-aminopropylamino)-4-(cyclohexylamino)pyrimidine-5-carboxamide,

2-(2-amino-2-oxoethylamino)-4-(cyclohexylamino)pyrimidine-5-carboxamide,

2-(2-aminoethylamino)-4-(cyclohexylamino)pyrimidine-5-carboxamide,

(S)-2-(2-aminopropylamino)-4-(cyclobutylamino)pyrimidine-5-carboxamide,

(R)-2-(1-amino-3-methyl-1-oxobutan-2-ylamino)-4-(cyclobutylamino)pyrimidine-5-carboxamide,

4-(cyclopentylamino)-2-(methylamino)pyrimidine-5-carboxamide, or

2-(1-acetylpiperidin-4-ylamino)-4-(cyclopropylamino)pyrimidine-5-carboxamide,

wherein when a C_{1-8} alkyl group is substituted, the C_{1-8} alkyl group is substituted with halogen, alkyl, hydroxyl, alkoxy, alkoxyalkyl, carboxy, nitro, cyano, thiol, thioether, imine, imide, amidine, guanidine, enamine, aminocarbonyl, acylamino, phosphonato, phosphine, thiocarbonyl, sulfonyl, sulfone, sulfonamide, ketone, aldehyde, ester, urea, urethane, oxime, hydroxyl amine, alkoxyamine, aralkoxyamine, N-oxide, hydrazine, hydrazide, hydrazone, azide, isocyanate, isothiocyanate, cyanate, thiocyanate, $B(OH)_2$, or O(alkyl)aminocarbonyl.

2. The compound of claim 1, wherein R^1 is a branched C_{1-8} alkyl.


,


,


,


,


,


,


,



,



,

or a pharmaceutically acceptable salt, tautomer, stereoisomer, or enantiomer thereof.

31. A compound of formula (IB):



(IB)

and pharmaceutically acceptable salts, tautomers, stereoisomers, enantiomers, and isotopologues~~, and prodrugs~~ thereof,

wherein:

R^3 is substituted or unsubstituted C_{1-8} alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted non-aromatic heterocyclyl, substituted or unsubstituted alkylcycloalkyl, or substituted or unsubstituted alkyl-(non-aromatic heterocyclyl);

R^4 is substituted or unsubstituted C_{1-8} alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted non-aromatic heterocyclyl;

provided the compound is not

4-(isopentylamino)-2-(3-(2-methylpiperidin-1-yl)propylamino)pyrimidine-5-carbonitrile;

(2S,2'S)-dimethyl 2,2'-(5-cyanopyrimidine-2,4-diyl)bis(azanediyl)bis(4-methylpentanoate);

(2S,2'S)-diethyl 2,2'-(5-cyanopyrimidine-2,4-diyl)bis(azanediyl)bis(3-methylbutanoate);

4-(cycloheptylamino)-2-(3-(2-methylpiperidin-1-yl)propylamino)pyrimidine-5-carbonitrile;

4-(4-methylcyclohexylamino)-2-(3-(2-methylpiperidin-1-yl)propylamino)pyrimidine-5-carbonitrile; or

2-(3-(diethylamino)propylamino)-4-(4-methylcyclohexylamino)pyrimidine-5-carbonitrile,

wherein when a C_{1-8} alkyl group is substituted, the C_{1-8} alkyl group is substituted with halogen, alkyl, hydroxyl, alkoxy, alkoxyalkyl, alkylamino, carboxy, nitro,



,



,



,



,

or a pharmaceutically acceptable salt, tautomer, stereoisomer, or enantiomer thereof.

51. A pharmaceutical composition comprising an effective amount of a compound of claim 1, 29, 30, 31, or 50, or a pharmaceutically acceptable salt, tautomer, isotopologue, or stereoisomer~~, or prodrug~~ thereof, and a pharmaceutically acceptable carrier, excipient or vehicle.

52. Use of a compound of claim 1, 29, 30, 31, or 50, or a pharmaceutically acceptable salt, tautomer, isotopologue, or stereoisomer~~, or prodrug~~ thereof for use in the manufacture of a medicament for inhibiting a kinase in a cell expressing said kinase.

53. The use of claim 52, wherein the kinase is one or more of JNK1 or JNK2.

54. Use of a compound of claim 1, 29, 30, 31, or 50 in the manufacture of a medicament for treatment or prevention of liver fibrotic-disorders, or diabetes or metabolic syndrome leading to liver fibrotic disorders.